Risperidone
- Generic Name
- Risperidone
- Brand Names
- Perseris, Risperdal, Rykindo, Uzedy, Okedi
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27FN4O2
- CAS Number
- 106266-06-2
- Unique Ingredient Identifier
- L6UH7ZF8HC
- Background
Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. Paliperidone, another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone).
...
- Indication
Risperidone is indicated for the treatment of schizophrenia and irritability associated with autistic disorder. It is also indicated as monotherapy, or adjunctly with lithium or valproic acid, for the treatment of acute mania or mixed episodes associated with bipolar I disorder.
...
- Associated Conditions
- Acute Mania, Irritability, Mixed manic depressive episode, Psychosis, Schizophrenia, Acute Manic episode, Agitated psychotic state
- Associated Therapies
- -
Risperidone Maintenance Treatment in Schizophrenia
- First Posted Date
- 2009-02-20
- Last Posted Date
- 2009-02-24
- Lead Sponsor
- Capital Medical University
- Target Recruit Count
- 404
- Registration Number
- NCT00848432
- Locations
- 🇨🇳
Beijing Anding Hospital of Capital Medical University, Beijing, China
A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients
- Conditions
- Interventions
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Denovo Biopharma LLC
- Target Recruit Count
- 261
- Registration Number
- NCT00845026
- Locations
- 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Samara, Russian Federation
Risperidone 1 mg Tablet in Healthy Subjects Under Fasting Conditions
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 30
- Registration Number
- NCT00830349
- Locations
- 🇨🇦
Anapharm Inc., Sainte-Foy, Quebec, Canada
Risperidone 1 mg Tablets Dosed in Healthy Subjects Under Fed Conditions
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 24
- Registration Number
- NCT00829894
- Locations
- 🇨🇦
Anapharm Inc., Sainte-Foy, Quebec, Canada
Paliperidone Extended-Release (ER) Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia
- First Posted Date
- 2009-01-23
- Last Posted Date
- 2011-12-23
- Lead Sponsor
- Chonnam National University Hospital
- Target Recruit Count
- 58
- Registration Number
- NCT00827840
- Locations
- 🇰🇷
Dept. of Psychiatry, Chonnam National Univeristy Hospital, Gwangju, Korea, Republic of
Pharmacological Treatment of Children and Adolescents With Severe Mood Dysregulation
- Conditions
- First Posted Date
- 2009-01-21
- Last Posted Date
- 2009-01-21
- Lead Sponsor
- Federal University of Rio Grande do Sul
- Target Recruit Count
- 20
- Registration Number
- NCT00825552
- Locations
- 🇧🇷
Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil
Dopamine D2 and D3 Receptor Occupancy and Clinical Response in Older Patients With Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2009-01-19
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- Centre for Addiction and Mental Health
- Target Recruit Count
- 14
- Registration Number
- NCT00825045
- Locations
- 🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
A Study to Evaluate the Efficacy and Safety of Seroquel in Chinese Han Patients With Schizophrenia
- First Posted Date
- 2009-01-06
- Last Posted Date
- 2010-06-15
- Lead Sponsor
- Shanghai Mental Health Center
- Target Recruit Count
- 120
- Registration Number
- NCT00817648
- Locations
- 🇨🇳
Mental Health Center of Luwan District, Shanghai, Shanghai, China
🇨🇳Shanghai Mental Health Center, Shanghai, Shanghai, China
🇨🇳Branch Hospital of Shanghai Mental Health Center, Shanghai, Shanghai, China
Treatment of Severe Childhood Aggression (The TOSCA Study)
- Conditions
- Interventions
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2017-07-26
- Lead Sponsor
- Michael Aman
- Target Recruit Count
- 168
- Registration Number
- NCT00796302
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Ohio State University Nisonger Center, Columbus, Ohio, United States
🇺🇸Case Western Reserve University, Cleveland, Ohio, United States
Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study)
- First Posted Date
- 2008-11-20
- Last Posted Date
- 2012-07-16
- Lead Sponsor
- Joseph Blader
- Target Recruit Count
- 270
- Registration Number
- NCT00794625
- Locations
- 🇺🇸
Stony Brook University Medical Center, Stony Brook, New York, United States
🇺🇸University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
🇺🇸North Shore - LIJ Health System, Zucker Hillside Hospital, Glen Oaks, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.